Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

In this article, we will take a look at the Top 11 CRISPR Stocks to Invest in. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...

Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotechnology company developing gene-editing therapies using CRISPR technology to treat genetic disorders by modifying patients’ genomes.